Zifi CV 100 Dry Syrup is a combination antibiotic formulation containing Cefixime 100 mg and Clavulanic Acid 62.5 mg per dose, designed for oral suspension use. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of gram-positive and gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing enzymatic degradation of the antibiotic, thereby overcoming resistance mechanisms in beta-lactamase producing bacteria. This synergistic combination is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, otitis media, skin and soft tissue infections, and other susceptible bacterial infections. Zifi CV 100 Dry Syrup is particularly useful in pediatric patients requiring an oral antibiotic with improved spectrum and resistance coverage. The dry syrup formulation allows for accurate dosing and improved palatability in children. Administration should follow the prescribed dosage regimen based on the severity of infection and patient weight. Caution is advised in patients with known hypersensitivity to cephalosporins or beta-lactam antibiotics. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and alterations in liver function tests. Proper reconstitution and storage as per manufacturer guidelines are essential to maintain drug stability and efficacy.